Goldman Sachs Downgrades Vertex (VRTX) to Sell; Becomes More Cautious on CF Combo Program
Tweet Send to a Friend
Vertex Pharma (Nasdaq: VRTX) shares are lower in early trading Friday following Goldman Sachs cutting its rating on the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
